NDAORALSUSPENSION
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
PURIXAN (mercaptopurine) by Viatris (2) is (tgns). Approved for acute lymphoblastic leukemia, leukemia, crohn's disease. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PURIXAN (mercaptopurine) is an oral purine analog suspension approved in 2014 for hematologic malignancies and Crohn's disease. It works by incorporating thioguanine nucleotides into DNA/RNA to arrest cell cycle and induce apoptosis in proliferating cancer cells. The mechanism also inhibits de novo purine synthesis and nucleotide interconversions.
$59KPart D
PeakNiche product in peak lifecycle with minimal commercial footprint; team likely small and specialized in hematologic/GI indications.
Mechanism of Action
(TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had…
Indications (3)
Worked on PURIXAN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.